Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
80.96
-0.75 (-0.92%)
At close: Jun 16, 2025, 4:00 PM
80.52
-0.44 (-0.54%)
Pre-market: Jun 17, 2025, 5:21 AM EDT
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$852,293
Profits / Employee
$232,453
Market Cap
203.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| AbbVie | 55,000 |
MRK News
- 21 hours ago - 2 Wonderful Dividends Practically Giving Themselves Away - Seeking Alpha
- 3 days ago - Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia
- 3 days ago - FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent - Business Wire
- 4 days ago - Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs - Business Wire
- 4 days ago - Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine - Reuters
- 4 days ago - Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 - Business Wire
- 4 days ago - Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate - Business Wire
- 6 days ago - Merck: Best Case For Option Collars We'll Ever See - Seeking Alpha